Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of DNL104 in Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of DNL104 in Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs DNL104 (Primary)
  • Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Neurodegenerative disorders
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Denali Therapeutics Inc
  • Most Recent Events

    • 19 Mar 2018 According to a Denali 10-K Sec filing report 2018, this phase I trial of DNL104 (a former RIPK1 inhibitor product candidate) was initiated in Sep 2016 and was subsequently discontinued in Apr 2017, based on liver function test abnormalities in some clinical trial healthy volunteer participants.
    • 03 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top